AU2013329199A1 - Combinations - Google Patents

Combinations Download PDF

Info

Publication number
AU2013329199A1
AU2013329199A1 AU2013329199A AU2013329199A AU2013329199A1 AU 2013329199 A1 AU2013329199 A1 AU 2013329199A1 AU 2013329199 A AU2013329199 A AU 2013329199A AU 2013329199 A AU2013329199 A AU 2013329199A AU 2013329199 A1 AU2013329199 A1 AU 2013329199A1
Authority
AU
Australia
Prior art keywords
compound
administered
cancer
amino
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013329199A
Other languages
English (en)
Inventor
Kurt Robert Auger
Vijay Gopal Reddy Peddareddigari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2013329199A1 publication Critical patent/AU2013329199A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013329199A 2012-10-12 2013-10-10 Combinations Abandoned AU2013329199A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261712869P 2012-10-12 2012-10-12
US61/712,869 2012-10-12
US201361833561P 2013-06-11 2013-06-11
US61/833,561 2013-06-11
PCT/US2013/064260 WO2014059095A1 (en) 2012-10-12 2013-10-10 Combinations

Publications (1)

Publication Number Publication Date
AU2013329199A1 true AU2013329199A1 (en) 2015-04-16

Family

ID=50477878

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013329199A Abandoned AU2013329199A1 (en) 2012-10-12 2013-10-10 Combinations

Country Status (11)

Country Link
US (1) US20160263116A1 (enExample)
EP (1) EP2906215A4 (enExample)
JP (1) JP2015533165A (enExample)
KR (1) KR20150067323A (enExample)
CN (1) CN104755079A (enExample)
AU (1) AU2013329199A1 (enExample)
BR (1) BR112015008155A2 (enExample)
CA (1) CA2888094A1 (enExample)
IN (1) IN2015DN02667A (enExample)
RU (1) RU2015117483A (enExample)
WO (1) WO2014059095A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
GB201510628D0 (en) * 2015-06-17 2015-07-29 Glaxosmithkline Ip No 2 Ltd Novel use
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2021253243B2 (en) * 2020-04-08 2024-01-18 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382906A (zh) * 2009-11-17 2015-03-04 葛兰素史密斯克莱有限责任公司 药物组合
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AU2012209100A1 (en) * 2011-01-26 2013-08-01 Board Of Regents The University Of Texas System Combinations

Also Published As

Publication number Publication date
JP2015533165A (ja) 2015-11-19
US20160263116A1 (en) 2016-09-15
CA2888094A1 (en) 2014-04-17
RU2015117483A (ru) 2016-12-10
BR112015008155A2 (pt) 2017-07-04
KR20150067323A (ko) 2015-06-17
EP2906215A1 (en) 2015-08-19
IN2015DN02667A (enExample) 2015-09-04
CN104755079A (zh) 2015-07-01
EP2906215A4 (en) 2016-05-18
WO2014059095A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
AU2012330885B2 (en) Oral immediate release formulations for substituted quinazolinones
JP6508544B2 (ja) 腫瘍を治療するための薬用組成物
JP2015536986A (ja) 併用療法
JP5903433B2 (ja) 癌の治療に有用なvegfr阻害剤およびmek阻害剤の医薬的組み合わせ
US20160375086A1 (en) Combination
CA2888094A1 (en) Combinations
EP2571358B1 (en) Combination therapy for treating cancer
JP2016106092A (ja) 組合せ
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
AU2012209100A1 (en) Combinations
US20180214451A1 (en) Combination
EP2603078A1 (en) Combination
JP2013526613A (ja) 組合せ
JP2015534987A (ja) 組合せ

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted